Parallax Volatility Advisers’s Blueprint Medicines BPMC Stock Holding History

Parallax Volatility Advisers’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-22,500	Closed	-$1.42M	–	2304
2023 Q2	$1.42M	Buy	+22,500	New	+$1.22M	﹤0.01%	1268
2019 Q3	–	Sell	-10,000	Closed	-$943K	–	2357
2019 Q2	$943K	Hold	10,000	–	–	﹤0.01%	1299
2019 Q1	$801K	Sell	10,000 -3,600	-26%	-$266K	﹤0.01%	1365
2018 Q4	$733K	Hold	13,600	–	–	﹤0.01%	1406
2018 Q3	$1.06M	Hold	13,600	–	–	﹤0.01%	1245
2018 Q2	$863K	Buy	+13,600	New	+$1.08M	﹤0.01%	1134

Other funds holding BPMC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Parallax Volatility Advisers's BPMC Position: Q3 2019 in Review

Parallax Volatility Advisers sold out of Blueprint Medicines (BPMC) in Q3 2019, closing a stake of 616 shares — an estimated $58K sold.

Parallax Volatility Advisers first reported a position in BPMC in Q4 2017 and held it in 5 quarters. The position peaked at $650K in Q4 2018. 220 funds tracked by Wall St. Rank hold BPMC as of Q3 2019.

Parallax Volatility Advisers reported no remaining Blueprint Medicines position as of Q3 2019 after selling out during the quarter.
Parallax Volatility Advisers sold 616 Blueprint Medicines shares in Q3 2019, an estimated $58K.
Parallax Volatility Advisers first reported a position in Blueprint Medicines in Q4 2017 and held it in 5 quarters.
Parallax Volatility Advisers's Blueprint Medicines position peaked at $650K in Q4 2018.
220 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2019.

Based on Parallax Volatility Advisers's 13F filing for Q3 2019, filed 14 Nov 2019.